Navneet Majhail, Physician-in-Chief of Blood Cancers at Sarah Cannon Cancer Network, shared a post on LinkedIn:
“The Sarah Cannon Cancer Network/Sarah Cannon Transplant and Cellular Therapy Network approach to outpatient administration of CAR T-cell therapy – manuscript available in November issue of JCO Journals.
The paper highlights our standardized approach to outpatient care using remote patient monitoring and provides guidance for programs that are interested in setting up an outpatient care delivery model.
Overall, ~80% of 350+ CART recipients across our network in 2025 will receive the majority of their care outside the hospital. Bottom line: ‘Safe and high-quality outpatient care requires involvement of a multidisciplinary team with clinical pathways for rapid triage and evaluation for CRS and ICANS and their management and, if necessary, timely transition of patients to a higher level of acute care.'”
Title: Outpatient Administration of Chimeric Antigen Receptor T-Cell Therapy Using Remote Patient Monitoring
Authors: Navneet S. Majhail, Tonya Cox, Stephanie Larson, Minoo Battiwalla, Aravind Ramakrishnan, Paul Shaughnessy, Michael Tees, Nicole Zahradka, Matt Wilkes, Jeremy Pantin
Read the Full Article on JCO Oncology Practice
More posts featuring Navneet Majhail.